


PRODUCT INFORMATION



Chelidonic Acid

Item No. 31324

CAS Registry No.: 99-32-1
Formal Name: 4-oxo-4H-pyran-2,6-dicarboxylic acid
Synonym: NSC 3979
MF: C₇H₄O₆
FW: 184.1
Purity: ≥95%
UV/Vis.: λ_{max}: 220, 272 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years
Item Origin: Synthetic



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Chelidonic acid is supplied as a crystalline solid. A stock solution may be made by dissolving the chelidonic acid in the solvent of choice, which should be purged with an inert gas. Chelidonic acid is soluble in the organic solvent DMSO at a concentration of approximately 1 mg/ml.

Chelidonic acid is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, chelidonic acid should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Chelidonic acid has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Chelidonic acid is a pyran that has been found in *C. majus* and has diverse biological activities.¹⁻³ It inhibits rat brain glutamate decarboxylase (K_i = 1.2 μM).² Chelidonic acid (20 mg/kg per day) reduces serum IL-6 and TNF-α levels, colonic COX-2 and prostaglandin E₂ (PGE₂; Item No. 14010) levels, and the disease activity index score in a mouse model of ulcerative colitis induced by dextran sulfate sodium (DSS; Item No. 23250).¹ It inhibits ovalbumin challenge-induced decreases in spleen IFN-γ levels and increases in serum, spleen, and nasal mucosa IgE levels, spleen IL-4 levels, and nasal mucosa eosinophil and mast cell infiltration in a mouse model of ovalbumin-sensitized allergic rhinitis when administered at a dose of 2 mg/kg.³

References

1. Kim, D.-S., Kim, S.-J., Kim, M.-C., *et al.* The therapeutic effect of chelidonic acid on ulcerative colitis. *Biol. Pharm. Bull.* **35(5)**, 666-671 (2012).
2. Porter, T.G. and Martin, C.L. Chelidonic acid and other conformationally restricted substrate analogues as inhibitors of rat brain glutamate decarboxylase. *Biochem. Pharmacol.* **34(23)**, 4145-4150 (1985).
3. Oh, H.-A., Kim, H.-M., and Jeong, H.-J. Beneficial effects of chelidonic acid on a model of allergic rhinitis. *Int. Immunopharmacol.* **11(1)**, 39-45 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM